REGENXBIO Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024, on March 13, 2025. Cash, cash equivalents, and marketable securities were $244.9 million as of December 31, 2024.
Total revenues for the full year 2024 were $83.3 million, down from $90.2 million in 2023, primarily due to a decrease in Zolgensma royalty revenues. The net loss for the full year 2024 was $227.1 million, or $4.59 per share, compared to $263.5 million, or $6.02 per share, in 2023.
The company expects its cash position, combined with the $110.0 million upfront payment from the Nippon Shinyaku collaboration, to fund operations into the second half of 2026. This guidance excludes potential future milestone payments or the monetization of a Priority Review Voucher.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.